Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of PA3670 in Healthy Chinese Subjects
NCT05851261Phase 1Completed
- Sponsor
- Apeloa
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PA3670 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Apeloa. Primary endpoints: Body temperature, Systolic and diastolic blood pressure and 10 more. Started Apr 2023; status: completed.
02
Drugs
PA3670
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05851261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851261.